Skip to main content
. 2021 Feb 16;7(1):e001519. doi: 10.1136/rmdopen-2020-001519

Figure 2.

Figure 2

Drug survival in the overall population and after their subdivision in two groups, according to the lines of the disease-modifying antirheumatic drugs treatment (group A, or bio-naïve vs group B, or non-bio-naïve patients) (A), dosage of secukinumab (150 vs 300 mg/injection) (B), gender (C) and body mass index (BMI) (overweight vs normal weight) (D).